Chronic Hepatitis C HCV genotype Any | peginterferon alfa-2b | Ribavirin | Therapeutic procedure First Hepatitis C
Item
participants with chronic hepatitis c virus (hcv)[any genotype] who received pegylated interferon alfa-2b plus ribavirin as first treatment for hepatitis c.
boolean
C0524910 (UMLS CUI [1,1])
C1148363 (UMLS CUI [1,2])
C1552551 (UMLS CUI [1,3])
C0796545 (UMLS CUI [2])
C0035525 (UMLS CUI [3])
C0087111 (UMLS CUI [4,1])
C0205435 (UMLS CUI [4,2])
C0019196 (UMLS CUI [4,3])
Hepatitis C RNA negative Hepatitis C virus RNA assay | Treatment completed | Hepatitis C virus RNA assay Limit of Detection
Item
negative hcv rna at the end of treatment (24 or 48 weeks according to the product labeling as appropriate), measured by the assay used at each institution. only institutions using an assay with a limit of detection of 50 iu/ml or less will be eligible.
boolean
C0855841 (UMLS CUI [1,1])
C1272251 (UMLS CUI [1,2])
C0580352 (UMLS CUI [2])
C1272251 (UMLS CUI [3,1])
C2718050 (UMLS CUI [3,2])
Childbearing Potential Contraceptive methods Unwilling | Premenopausal state | Postmenopausal state Duration | Barrier Contraception Double | Vaginal contraceptive diaphragm | Female Condoms | Vaginal Spermicides | Intrauterine Devices | Contraceptives, Oral | Injectable contraception | Subcutaneous contraceptive Hormonal | Partner Male sterilization
Item
women of childbearing potential (i.e., premenopausal women and women who are less than 6 months postmenopausal) who will not use an appropriate contraceptive method during the course of the clinical study. appropriate contraceptives include double barrier methods (eg, diaphragm or condom plus spermicide), intrauterine device, oral, injectable or subcutaneous hormonal contraceptive, or surgically sterilized partner.
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
C0558080 (UMLS CUI [1,3])
C0232969 (UMLS CUI [2])
C0232970 (UMLS CUI [3,1])
C0449238 (UMLS CUI [3,2])
C0004764 (UMLS CUI [4,1])
C0205173 (UMLS CUI [4,2])
C0042241 (UMLS CUI [5])
C0221829 (UMLS CUI [6])
C0087145 (UMLS CUI [7])
C0021900 (UMLS CUI [8])
C0009905 (UMLS CUI [9])
C1262153 (UMLS CUI [10])
C0459222 (UMLS CUI [11,1])
C0458083 (UMLS CUI [11,2])
C0682323 (UMLS CUI [12,1])
C0024559 (UMLS CUI [12,2])
Treatment completed | peginterferon alfa-2b | Ribavirin
Item
completed treatment with pegylated interferon alfa-2b plus ribavirin more than 4 weeks before study entry.
boolean
C0580352 (UMLS CUI [1])
C0796545 (UMLS CUI [2])
C0035525 (UMLS CUI [3])
Hepatitis C RNA positive | Treatment completed
Item
positive hcv rna at the end of treatment (24 or 48 weeks according to the product labeling as appropriate).
boolean
C0855842 (UMLS CUI [1])
C0580352 (UMLS CUI [2])
Therapeutic procedure short-term | Enrollment Period failed
Item
participants treated for a period shorter than the enrollment period.
boolean
C0087111 (UMLS CUI [1,1])
C0443303 (UMLS CUI [1,2])
C1516879 (UMLS CUI [2,1])
C1948053 (UMLS CUI [2,2])
C0231175 (UMLS CUI [2,3])
HIV coinfection
Item
co-infection with human immumodeficiency virus (hiv).
boolean
C4062778 (UMLS CUI [1])
HBV coinfection
Item
co-infected with hepatitis b virus (hbv).
boolean
C2242656 (UMLS CUI [1])